Faes Farma, S.A.
FAE.MC

$1.23 B
Marketcap
$3.96
Share price
Country
$0.05
Change (1 day)
$4.14
Year High
$3.10
Year Low

Faes Farma, S.A., a pharmaceutical company, researches, develops, produces, and commercializes pharmaceutical products and raw materials in Spain and internationally. The company's product portfolio includes prescription drugs, generic drugs, over-the-counter (OTC) drugs, food supplements, baby foods, and other health products. It offers Actimag, a magnesium pidolate; Bilaxten, an anti-allergic; Bronquidiazina CR, an anti-infective; Claversal for ulcerative colitis and Crohn's disease; Dezacor, a corticoid; Dolotren, an anti-inflammatory; Dolotren Gel; Dynamogen, an anti-anorexic; Ferroprotina, an anti-anaemic; Hidroferol; Lipofen; Positon for dermatitis; strength builder products, such as Potenciator and Surmenalit; Pruina, a laxative; Robaxisal Compuesto, a muscle relaxant and analgesic; Trausan, a citicoline; Venosmil, a venous vasoprotector; Venosmil Gel; and Yendol, an anti-flu. The company also provides Bilastine, an antihistamine molecule for the treatment of allergic rhino conjunctivitis and urticarial; Calcifediol for bone metabolism; Deflazacort to treat osteoarticular disease; Hidrosmin for venous insufficiency; and Mesalazine to treat digestion problems. It also exports its products. Faes Farma, S.A. was founded in 1933 and is headquartered in Leioa, Spain.

marketcap

P/B ratio for Faes Farma, S.A. (FAE.MC)

P/B ratio as of 2023: 1.48

According to Faes Farma, S.A.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 1.48. At the end of 2022 the company had a P/B ratio of 1.78.

P/B ratio history for Faes Farma, S.A. from 2003 to 2023

P/B ratio at the end of each year

Year P/B ratio
2023 1.48
2022 1.78
2021 1.89
2020 2.07
2019 3.31
2018 2.20
2017 2.39
2016 2.97
2015 2.73
2014 1.81
2013 2.99
2012 1.83
2011 1.49
2010 3.11
2009 4.87
2008 2.34
2007 6.59
2006 14.43
2005 8.57
2004 13.28
2003 13.85